Trial Profile

A Clinical Trial of OPN-019 to Reduce Illness and Transmission of the COVID-19 Virus

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 05 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OPN-019 (Primary)
Indications COVID 2019 infections
Focus Adverse reactions
Sponsors OptiNose

Most Recent Events

05 Jul 2020 New trial record
30 Jun 2020 According to an OptiNose media release, the Company expects to be able to rapidly progress to a meeting with FDA to discuss an IND and then onward to clinical trials.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com